- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears AI-Powered Bladder Volume Measurement for Handheld Ultrasound
Offering enhanced utility for assessing urinary incontinence, bladder emptying and urinary retention, the Clarius Bladder AI ultrasound software reportedly provides bladder volume measurement in seconds.
The Clarius Bladder AI ultrasound software, which may have significant utility in acute care settings, urology clinics and nursing homes, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Clarius Mobile Health, the manufacturer of Clarius Bladder AI, said the software provides automated bladder volume measurements in seconds.
The artificial intelligence (AI)-powered software is particularly useful for assessing urinary retention and bladder emptying in cases involving obstruction of the urinary tract or patients with a neurogenic bladder, according to the company.
Reportedly capable of providing automated bladder volume measurements in seconds, Clarius Bladder AI is particularly useful for assessing urinary retention and bladder emptying in cases involving obstruction of the urinary tract or patients with a neurogenic bladder, according to Clarius Mobile Health, the manufacturer of the software.
“Bladder AI removes the tedious steps of calculating bladder volume in my patients with urinary retention,” says Oron Frenkel, M.D., an emergency physician who practices in the United States and Canada. "It helps me quickly identify who needs a catheter placed or further investigation for any urinary or abdominal pain symptoms."
Clarius Mobile Health noted that other clinical applications for Clarius Bladder AI include evaluation of upper urinary tract disease in acute care settings and urinary incontinence, which may affect up to 70 percent of nursing home residents.
Clarius Bladder AI is available with the Clarius Mobile Health handheld ultrasound models PAL HD3, PA HD3 and C3 HD3, according to the company.
Mammography Study Suggests DBT-Based AI May Help Reduce Disparities with Breast Cancer Screening
December 13th 2024New research suggests that AI-powered assessment of digital breast tomosynthesis (DBT) for short-term breast cancer risk may help address racial disparities with detection and shortcomings of traditional mammography in women with dense breasts.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
